Business
Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (...
About this update from Profound Medical Corp
[{"type":"text","content":"Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting\nTORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that the interventional MRI (“iMRI”) TULSA Procedure™ will be highlighted in several presentations at the 2026 Society of Interventional Radiology (“SIR”) Annual Scientific Meeting, to be held in Toronto, ON, April 11-15. The TULSA Procedure, performed using the TULSA-PRO® system, represents a major advancement in prostate care, and is used by physicians to treat men with prostate cancer and/or benign prostatic hyperplasia (“BPH”, also known as an enlarged prostate). Robotically controlled directional ultrasound is delivered from inside the urethra to precisely and gently heat prostate tissue to ‘kill temperature’ (55-57°C), while protecting surrounding nerves and anatomy. Real-time MRI thermography enables continuous visualization and autonomous temperature adjustment throughout the procedure. This level of precision allows physicians to tailor therapy to each patient, resulting in no procedural blood loss, no overnight hospital stay, and a quicker return to everyday life, while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction. TULSA-PRO will be front-and-center in the session titled \"Men's Health 1\" on April 12th from 3:00-4:30 p.m. EDT with five oral presentations: Joseph J. Busch, Jr., M.D., a board-certified radiologist and Founder of the Busch Center in Alpharetta, GA, will give a presentation titled \"Robotic Assisted MRI-Guided Transurethral Ultrasound Ablation (TULSA) for MRI-visible Prostate Cancer at the Extreme Apex\";Dr. Joseph Busch will also give a presentation titled \"Robotic Assisted MRI-Guided Transurethral Ultrasound Ablation in Recurrent Prostate Cancer: A Retrospective Analysis\";Arsalan Nadeem, MBBS, a Postdoctoral Research Fellow in the...